Core Viewpoint - The company, Xingqi Eye Pharmaceutical, has announced the completion of the first subject enrollment in the Phase II clinical trial for its drug, Voriconazole Eye Drops, aimed at treating fungal keratitis [1] Group 1: Clinical Trial Details - Voriconazole Eye Drops are classified as a chemical drug of category 2.2, specifically targeting fungal keratitis [1] - The Phase II clinical trial is a randomized, positive-controlled, multi-center exploratory study designed to preliminarily assess the efficacy and safety of Voriconazole Eye Drops in subjects with fungal keratitis [1] - The trial aims to explore safe and effective drug concentrations for the subsequent Phase III clinical trial [1] Group 2: Market Context - Currently, there are no approved Voriconazole Eye Drops available in the market [1]

兴齐眼药公告，公司研发的伏立康唑滴眼液于今日完成了首例受试者入组，正式进入II期临床试验。伏 立康唑滴眼液Ⅱ期临床试验研究为一项随机、阳性对照、多中心探索性试验，以期初步探索伏立康唑滴 眼液在真菌性角膜炎受试者中的有效性和安全性，为III期临床试验探索安全、有效的药物浓度。 ...

格隆汇8月12日丨兴齐眼药(300573.SZ)公布，公司研发的伏立康唑滴眼液于今日完成了首例受试者入 组，正式进入Ⅱ期临床试验。伏立康唑是新一代三唑类抗真菌药，具有抗菌谱广、毒性低及抗菌效力强 的特点。 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2025-032 沈阳兴齐眼药股份有限公司 关于伏立康唑滴眼液 II 期临床试验首例受试者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）研发的伏立康唑滴眼液于 今日完成了首例受试者入组，正式进入Ⅱ期临床试验。现将有关内容公告如下： 一、基本情况 真菌性角膜炎是我国常见的致盲性眼病，发病率高，临床诊断困难，且治疗 周期长，容易复发，给患者带来极大的痛苦。伏立康唑是新一代三唑类抗真菌药， 具有抗菌谱广、毒性低及抗菌效力强的特点。 伏立康唑滴眼液Ⅱ期临床试验研究为一项随机、阳性对照、多中心探索性试 验，以期初步探索伏立康唑滴眼液在真菌性角膜炎受试者中的有效性和安全性， 为Ⅲ期临床试验探索安全、有效的药物浓度。 三、同类药品的情况 本次公告的伏立康唑滴眼液是以伏立康唑为活性成份的眼用制剂，适应症为 药物名称：伏立康唑滴眼液 剂型：滴眼剂 注册分类：化学药品 2.2 类 适应症：真菌性角膜炎 临床试验分期：Ⅱ期 申办方：沈阳兴齐眼药股份有限公司 二、临床试验相 ...

每经AI快讯，有投资者在投资者互动平台提问：董秘你好，公司2024年营收全部来自国内市场。公司 有无计划发展国外市场？具体规划如何？美国对药品加征至高250%的关税对公司有无影响？ 兴齐眼药（300573.SZ）8月7日在投资者互动平台表示，公司目前主营业务聚焦于国内市场，暂不涉及 对美出口，美国关税对公司经营不构成影响。 （文章来源：每日经济新闻） ...

格隆汇8月7日丨兴齐眼药(300573.SZ)在互动平台表示，公司目前主营业务聚焦于国内市场，暂不涉及 对美出口，美国关税对公司经营不构成影响。 ...

Group 1 - The total compensation for CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - Cheng Yanan, CFO of Shenyang Xingqi Eye Pharmaceutical Co., Ltd., earned 1.88 million yuan in 2024, a 10.67% increase from the previous year [1][2] - Despite the increase in Cheng's salary, the company's stock price fell by 61.73%, leading to questions about its market value management [2] Group 2 - Shenyang Xingqi Eye Pharmaceutical reported a revenue of 1.943 billion yuan in 2024, a year-on-year increase of 32.42%, and a net profit of 338 million yuan, up 40.84% [2] - The significant disparity between the management's compensation and the company's stock performance has sparked discussions in the market [2] - Cheng Yanan's daily salary of 7,520.8 yuan stands out particularly against the backdrop of the company's declining stock price [2]

Core Viewpoint - The market shows a strong sentiment with significant sector rotation, indicating potential investment opportunities in undervalued sectors like photovoltaics and technology [1][2]. Group 1: Market Performance - As of July 29, 2025, the CSI A500 Index (000510) increased by 0.14%, with notable gains in stocks such as Tianfu Communication (300394) up 12.77% and Tiger Medical (300347) up 11.05% [1]. - The A500 ETF fund (512050) rose by 0.10%, with the latest price at 1.02 yuan [1]. Group 2: Sector Analysis - Short-term analysis suggests a significant rotation effect in the market, with a focus on undervalued sectors like photovoltaics for potential valuation recovery [1]. - Long-term, the technology sector is expected to provide narrative effects, with recommendations for a barbell strategy that includes increasing allocations to technology and communication sectors while maintaining dividend stock allocations [1]. Group 3: Index Composition - As of June 30, 2025, the top ten weighted stocks in the CSI A500 Index include Kweichow Moutai (600519), Contemporary Amperex Technology (300750), and Ping An Insurance (601318), collectively accounting for 20.67% of the index [2]. - The top ten stocks by weight are as follows: - Kweichow Moutai: 0.09% increase, 3.81% weight - Contemporary Amperex Technology: 1.58% increase, 2.88% weight - Ping An Insurance: 0.73% decrease, 2.58% weight - China Merchants Bank: 0.20% decrease, 2.46% weight - Industrial Bank: 0.61% decrease, 1.68% weight - Yangtze Power: 0.07% increase, 1.59% weight - Midea Group: 0.76% decrease, 1.53% weight - Zijin Mining: 1.06% decrease, 1.39% weight - BYD: 0.79% increase, 1.30% weight - Eastmoney Information: 0.62% decrease, 1.26% weight [4].

Group 1 - The A-share ophthalmology sector experienced a volatile rebound, with Tianmu Pharmaceutical hitting the daily limit up [1] - Other companies such as Xingqi Eye Medicine, Laimei Pharmaceutical, Nuo Silan De, and Daheng Technology also saw increases in their stock prices [1]

Core Insights - The increasing prevalence of electronic devices has heightened awareness of the potential visual hazards associated with prolonged screen exposure, leading to a surge in demand for lutein as a vital nutrient for eye health [1][3] - The children's market for lutein products has become a competitive battleground, driven by rising concerns among parents regarding children's vision health [1][15] Market Overview - The domestic market for lutein is estimated to reach nearly 6 billion yuan, with a compound annual growth rate (CAGR) of 19.8% from 2020 to 2024, significantly outpacing global market growth [4][3] - The eye care sector is the primary contributor to market growth, with annual sales of lutein soft capsules exceeding 200 million bottles [4] Competitive Landscape - The lutein market is characterized by intense competition across both health food and regular food sectors, with no dominant brand currently leading the market [2][20] - Major players in the extraction and processing segment include Chenguang Biotech, DSM, and Kemin, creating a "three-legged" competitive structure [4] Product Development - The market has seen a rapid increase in the registration of lutein health products, with over 150 products registered, primarily in capsule form [7][8] - Innovative product forms such as gummies and ready-to-drink beverages are gaining popularity, with the market for lutein gummies expected to exceed 1.5 billion yuan by 2024 [11] Consumer Trends - The demand for lutein products is driven by the rising incidence of myopia among children, with the overall myopia rate in Chinese children reaching 51.9% [18] - The average price of imported lutein products is significantly higher than that of domestic products, with imported items often exceeding 100 yuan per unit [17] Regulatory Environment - Lutein products are primarily classified as health foods and must undergo a registration process, as they are not included in the approved health food ingredient directory [9][14] - The lack of a clear definition for dietary supplements in China has led to many imported lutein products being marketed as regular foods, despite their health claims [13] Future Outlook - The lutein market is expected to continue evolving, with a focus on product differentiation and innovation to address the challenges of market saturation and consumer trust [20][22] - Companies are encouraged to invest in research and development to create unique products that can withstand competition and avoid the pitfalls of market homogenization [22]